SynAI: an AI-driven cancer drugs synergism prediction platform.
Journal
Bioinformatics advances
ISSN: 2635-0041
Titre abrégé: Bioinform Adv
Pays: England
ID NLM: 9918282081306676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
07
2023
revised:
13
10
2023
accepted:
08
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
The SynAI solution is a flexible AI-driven drug synergism prediction solution aiming to discover potential therapeutic value of compounds in early stage. Rather than providing a finite choice of drug combination or cell lines, SynAI is capable of predicting potential drug synergism/antagonism using The evaluation version of SynAI is freely accessible online at https://synai.crownbio.com.
Identifiants
pubmed: 38023331
doi: 10.1093/bioadv/vbad160
pii: vbad160
pmc: PMC10660295
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vbad160Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Déclaration de conflit d'intérêts
None declared.
Références
Cancer Cell. 2020 Nov 9;38(5):672-684.e6
pubmed: 33096023
J Cheminform. 2020 Jun 12;12(1):43
pubmed: 33431010
Cancer Res. 2017 Jul 1;77(13):3564-3576
pubmed: 28446463
Nucleic Acids Res. 2020 Jan 8;48(D1):D871-D881
pubmed: 31665429
Chem Sci. 2017 Oct 31;9(2):513-530
pubmed: 29629118
Bioinformatics. 2016 Dec 15;32(24):3782-3789
pubmed: 27540269
Bioinformatics. 2018 May 1;34(9):1538-1546
pubmed: 29253077
Brief Bioinform. 2022 Jan 17;23(1):
pubmed: 34571534
Nature. 2022 Mar;603(7899):166-173
pubmed: 35197630
Front Chem. 2019 Jul 16;7:509
pubmed: 31380352
NPJ Syst Biol Appl. 2020 Jun 2;6(1):16
pubmed: 32487991
Nucleic Acids Res. 2023 Jan 6;51(D1):D1373-D1380
pubmed: 36305812